Cabozantinib hydrochloride

产品编号: T5164 别名:

盐酸卡博替尼,Cabozantinib hydrochloride (849217-68-1(free base)),BMS-907351,XL184

Cabozantinib hydrochloride 是一种有效的泛酪氨酸激酶抑制剂，可抑制 VEGFR2、c-Met、Kit、Axl 和 FLT4（IC50：0.035、1.3、4.6、7 和 6 nM）。

陶术生物的所有产品和服务仅用于科学研究，我们不为任何个人用途提供产品和服务。

Cabozantinib hydrochloride Chemical Structure

CAS：1817759-42-4

规格	库存	价格/RMB	数量
{{item.packagingtext}}	{{item.goodshuoqi}}	{{item.moneyunit}} {{item.finalprice}} {{item.pricetext==null\|\|item.pricetext==''?pricetext:item.pricetext}}

生物活性化学信息储存和溶解度信息参考文献引用文献

产品描述

Cabozantinib (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6 nM).

体外活性

SR1001 binds specifically to the ligand-binding domains of RORα and RORγt, inducing a conformational change within the ligand-binding domain, resulting in suppression of the receptors' transcriptional activity. SR1001 inhibited the development of murine T(H)17 cells. Furthermore, SR1001 inhibited the expression of cytokines when added to differentiated murine or human T(H)17 cells [1]. Treatment with the RORγT inhibitor SR1001 to abrogate Th17 cell function reduced Th17-dependent learned helplessness [2].

体内活性

After myelin oligodendrocyte glycoprotein (MOG35–55) immunization at day 0, experimental autoimmune encephalomyelitis (EAE) mice were treated with SR1001 (25 mg/kg, b.i.d. i.p.) for the duration of the study. Further analysis of spinal cords from mice harvested at day 18 post-immunization revealed that SR1001 repressed Il17a mRNA expression by ~60%, as well as reduced Il21, and Il22 mRNA expression [1]. When these mice were injected with SR1001, the circadian rhythm of CS expression was eliminated [3].

细胞实验

CD4+ T cells were isolated as described previously and in the Supplementary Materials. CD4+ T cells cultured with splenic feeder cells were activated with 2.5 μg/mL of anti-CD3 (clone 145–11), and differentiated to Th17 cells by addition of IL-6 (20 ng/mL; Peprotech), TGFβ (5 ng/mL), anti-IL-4 (10 μg/mL; clone 11B11, UAB core facility) and anti-IFNγ (10 μg/mL; clone XMG1.2, UAB core facility). After 5 days of differentiation toward Th17 cells, cells were recovered after histopaque gradient purification and resuspended in PBS. An aliquot of cells was used to evaluate the percent of Th17 cells (~40%) and ~10–20×106 undifferentiated CD4+ T or Th17 cells were injected in 500 μL PBS by tail vein 48 h prior to behavioral testing. Where indicated, mice were injected intraperitoneally with 100 μg anti-IL-17A, or 125 μg SR1001 daily beginning 1 day before Th17 cell transfer, and this was continued throughout the experiment. As controls, mice were injected i.v. with ~10–20×106 CD4+ T cells to evaluate the effect of non-differentiated cells, or with 500 μL PBS to mimic the stress of tail vein i.v. injection 48 h prior to behavioral testing. Intracellular cytokine staining was carried out as described previously and in the Supplementary Information [2].

动物实验

For circadian gene expression experiments male C57BL6 mice (8–10 weeks of age) were either maintained on a L:D (12h∶12h) cycle or on constant darkness (1 day). At the circadian time (CT) 0 animals were administered a single dose of 25 mg/kg SR1001 (i.p.) and groups of animals (n?=?6) were sacrificed at CT0, CT6, CT12, and CT18. Gene expression was determined by real-time qPCR. Gene expression was normalized to Cyclophin b in all experiments [3].

Cas No.

1817759-42-4

分子式

C28H25ClFN3O5

分子量

537.96

别名

Cabozantinib hydrochloride (849217-68-1(free base));BMS-907351;XL184;盐酸卡博替尼;Cabozantinib hydrochloride

参考文献

[1]Torres KE, et al. Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors.Clin Cancer Res. 2011 Jun 15;17(12):3943-55.[2]Yakes FM, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther, 2011, 10(12), 2298-2308.[3]You WK, et al. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res, 2011, 71(14), 4758-4768.

储存和溶解度

DMSO:80 mg/mL
Powder: -20°C for 3 years
In solvent: -80°C for 2 years

剂量换算 Cabozantinib hydrochloride 1817759-42-4

对于各种应用，安全且有效的用药剂量是很有必要的了解更多

体内实验配液计算器

第一步：请输入动物实验的基本信息

剂量 mg/kg

每只动物体重 g

给药体积 ul

动物数量

第二步：请输入动物体内配方组成，不同的产品配方组成不同，如有配方需求，可先联系我们提供正确的体内配方。

% DMSO +

% +

% Tween 80 +

% ddH₂O

% DMSO +

重置计算

计算结果如下:

工作液浓度: mg/ml;

母液配置方法: mg 药物溶于 μL DMSO (母液浓度为 mg/mL)，如您需要配置的浓度超过该产品的溶解度，请先与我们联系。

体内配方的制备方法：取 μL DMSO 主液，加入 μL PEG300，混匀澄清，再加 μL Tween 80，混匀澄清，再加 μL ddH₂O, 混匀澄清。

备注:

要按顺序从左向右依次添加助溶剂。可配合物理方法，如涡流、超声波或热水浴使之帮助溶解。

计算器

摩尔计算器可以帮助您计算

制备已知体积和浓度溶液所需的化合物质量
将已知质量的化合物溶解到所需浓度所需的溶液体积
已知质量的化合物在一定体积内形成的溶液的浓度

质量

浓度

体积

分子量

重置计算

稀释计算器可以帮助您计算

制备已知体积和浓度溶液所需的化合物质量
将已知质量的化合物溶解到所需浓度所需的溶液体积
已知质量的化合物在一定体积内形成的溶液的浓度

浓度（起始）

体积（起始）

浓度（终点）

体积（终点）

重置计算

配液计算器可以帮助您计算

重组计算器可帮助您快速计算试剂的体积，以重组您的小瓶。

溶液体积

质量

配液浓度

重置计算

配液计算器可以帮助您计算

输入化合物的化学式以计算其摩尔质量和元素组成
提示：化学式需区分大小写

分子结构式

总分子量

g/mol

重置计算

技术支持

在抑制剂处理说明中可以找到您可能遇到的问题的答案。主题包括如何准备储备溶液，如何存储产品以及基于细胞的测定和动物实验需要特别注意的问题。

Keywords

inhibit Cabozantinib hydrochloride CD135 Mer Fms like tyrosine kinase 3 VEGFR Inhibitor BMS 907351 SCFR Axl Cluster of differentiation antigen 135 XL-184 c-Kit c-Met/HGFR TAM Receptor Cabozantinib hydrochloride (849217-68-1(free base)) Vascular endothelial growth factor receptor BMS907351 XL 184 angiogenesis BMS-907351 CD117 FLT3 HT1080 XL184 A431 antiangiogenic Apoptosis Tyro3 Cabozantinib 盐酸卡博替尼 B16F10 cells 1817759-42-4

Cabozantinib hydrochloride 相关推荐

相关化合物库推荐该产品包含在如下化合物库中：

注册成功

Cabozantinib hydrochloride

盐酸卡博替尼,Cabozantinib hydrochloride (849217-68-1(free base)),BMS-907351,XL184

摩尔计算器可以帮助您计算

稀释计算器可以帮助您计算

配液计算器可以帮助您计算

配液计算器可以帮助您计算